AbbVie and ADARx Collaborate on Next-Generation siRNA Therapies for Neuroscience, Immunology, and Oncology

Strategic Insights -

AbbVie and ADARx Pharmaceuticals have announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology, and oncology. This partnership will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, combined with AbbVie's expertise in antibody engineering and antibody drug conjugates (ADCs), to develop innovative solutions for difficult-to-treat diseases.

Key Takeaways:

  • The collaboration will focus on developing siRNA therapeutics for neuroscience, immunology, and oncology, with potential applications in treating diseases such as Alzheimer's, Parkinson's, and cancers.
  • ADARx will receive a $335 million upfront payment, as well as several billion dollars in contingent payments, including option-related fees, milestone payments, and tiered royalties.
  • AbbVie will contribute its expertise in antibody engineering, ADCs, and tissue delivery approaches to augment ADARx's discovery efforts.
  • The partnership has the potential to unlock tremendous clinical and commercial potential across multiple disease areas.
  • ADARx's proprietary RNA technology has the potential to enable sustained and precise mRNA silencing.

Statistics:

  • $335 million upfront payment to ADARx.
  • Several billion dollars in contingent payments, including option-related fees, milestone payments, and tiered royalties.
  • Potential applications in treating diseases such as Alzheimer's, Parkinson's, and cancers.
  • ADARx's pipeline includes clinical-stage programs for complement-mediated, cardiovascular, and thrombotic diseases, as well as preclinical discovery programs in obesity and neurodegeneration.

Sources:

  • AbbVie's press release, "AbbVie and ADARx Pharmaceuticals Announce Collaboration to Develop Next-Generation RNA Therapies for Neuroscience, Immunology and Oncology" (May 14, 2025)
  • ADARx Pharmaceuticals' press release, "ADARx Pharmaceuticals and AbbVie Announce Collaboration and License Option Agreement to Develop Next-Generation RNA Therapies" (May 14, 2025)